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Abstract
Purpose of Review Bariatric surgery was initially intended to
reduce weight, and only subsequently was the remission of
type two diabetes (T2D) observed as a collateral event. At the
moment, the term “metabolic surgery” is used to underline the
fact that this type of surgery is performed specifically to treat
diabetes and its metabolic complications, such as
hyperlipidemia.
Recent Findings Randomized, controlled studies have recent-
ly supported the use of bariatric surgery, and in particular of
Roux-en-Y gastric bypass (RYGB) and biliopancreatic diver-
sion (BPD) as an effective treatment for decompensated T2D.
The lesson learned from these randomized and many other
non-randomized clinical studies is that the stomach and the
small intestine play a central role in glucose homeostasis.
Bypassing the duodenum and parts of the jejunum exerts a
substantial effect on insulin sensitivity and secretion. In fact,
with BPD, nutrient transit bypasses duodenum, the entire je-
junum and a small portion of the ileum, resulting in reversal of
insulin sensitivity back to normal and reduction of insulin
secretion, whereas RYGB has little effect on insulin resistance
but increases insulin secretion. Hypotheses concerning the
mechanism of action of metabolic surgery for diabetes remis-
sion vary from theories focusing on jejunal nutrient sensing, to
incretin action, to the blunted secretion of putative insulin
resistance hormone(s), to changes in the microbiota.
Summary Whatever the mechanism, metabolic surgery has
the undoubted merit of exposing the central role of the small
intestine in insulin sensitivity and glucose homeostasis.
Keywords Bariatric surgery .Gastricbypass .Biliopancreatic
bypass . Sleeve gastrectomy . Diabetes mellitus . Obesity
Introduction
In the last few years, a great deal of attention has been focused
on the effects of bariatric surgery on diabetes remission and
changes in glucose homeostasis. In fact, a foremost achieve-
ment of bariatric surgery has been to uncover the role of the
small intestine in glucose metabolism.
The term “bariatric” derives from the Greek word “baros”,
meaning weight. Bariatric surgery was in fact developed to
cure morbidly obese subjects. The idea of a surgical treatment
of obesity developed in the early 1950s fortuitously from the
observation that patients that underwent gastrointestinal resec-
tions for various reasons were likely to lose weight.
An international consensus conference held in Rome in
2007 - the “Diabetes Surgery Summit”—underlined the need
to use the adjective “metabolic” instead of “bariatric” in order
to highlight the efficacy of bariatric surgery from the metabol-
ic point of view even in the absence of weight reduction [1].
Indeed, the designation of “metabolic surgery”was previously
used by Buchwald and Varco [2] for some operations like the
portal diversion to improve glycogen storage diseases or the
partial ileal bypass for hyperlipidemia.
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In view of the weight independent effects of some types of
gastrointestinal surgery for obesity, Rubino [3] proposed to use
metabolic surgery not only for uncontrolled T2D, but also for
patients with the metabolic syndrome, non-alcoholic
steatohepatitis (NASH), and increased cardiovascular risk, pre-
suming a neuroendocrinemechanism of action for this surgery.
Here, we seek to briefly summarize recent findings from
randomized trials on the impact of bariatric surgery on meta-
bolic outcomes, and devote the remainder this article to pre-
senting a new perspective on the role played by the small
intestine in driving the changes in insulin sensitivity and se-
cretion and glycemic control that occur after some types of
bariatric surgery. A better understanding of gut function in
glucose disposal might help to develop, in the near future, a
medical treatment for T2D that mimics the effects of gastro-
intestinal surgery.
Review of Recent Randomized Trials
Randomized controlled trials (RCT) have shown that
bariatric/metabolic surgery is effective in treating type 2 dia-
betes mellitus. An extensive review of the literature at this
regard is behind our scope; therefore, we have summarized
only the results of some relevant RCTs.
The first evidence of the efficacy of bariatric surgery on
T2DM is that fromDixon et al.’s [4] RCTshowing that T2DM
remission was present in 73% of the patients who underwent
LAGB and in 13% of those in the conventional therapy group.
Shauer et al. [5] demonstrated that the proportion of pa-
tients achieving a glycated hemoglobin (HbA1c) level
≤6.0% 12 months after treatment was 12% in the medical-
therapy group versus 42% in the RYGB (P= 0.002) and
37% in the SG group (P=0.008). Therefore, at least at 1 year
after surgery there was no difference between the two types of
operation. However, the same authors reported that at 3 years
following surgery [6], the criterion for the primary end point
was met by 5% of the patients in the conventional therapy
group and in 38% of those in the RYGB group (P<0.001)
and 24% of those in the SG group (P=0.01), thus showing a
more sustained effect of the RYGB procedure as compared
with SG. Importantly, quality of life was significantly better in
the two surgical arms than in the medical arm.
Having as primary end point a diabetes remission rate (de-
fined as a fasting glucose level of <100 mg per deciliter
[5.6 mmol per liter] and a glycated hemoglobin level of
<6.5% in the absence of pharmacologic therapy) at 2 years after
intervention, Mingrone et al. [7] demonstrated that 75% of the
patientswhohadundergoneRYGBand95%BPDhaddiabetes
remission (P<0.001 for both comparisons versus medical-
therapy group). However, in the long term (5 years follow-up)
50% of the surgical patients (37% in the RYGB and 63% in the
BPD group) maintained diabetes remission (P=0.0007 versus
medically treated patients)while the other patients had diabetic
relapse [8], although the number of anti-diabetic, anti-
hypertensiveandhypolipidemicdrugswere significantly lower
while the quality of life was significantly better in the surgical
than in the medical arm.
MetabolicsurgeryiseffectiveintreatingT2DMalsoinpatients
with a BMI <35 kg/m2 as shown by Cohen et al. [9] at 6 years
followingRYGBwith a durable diabetes remission that occurred
in 88% of cases andwith glycemic improvement in 11%.
In the Crossroad RCT, Cummings et al. [10] compared
RYGB with intensive lifestyle and medical intervention
(ILMI) in T2DM patients with a BMI <35 kg/m2 and found
that diabetes remission (HbA1c <6.0% [<42.1 mmol/mol], off
all diabetes medicines) at 1 year was achieved in 60.0% of
RYGB and in 5.9% of ILMI (P=0.002).
There RCTs show that bariatric/metabolic surgery is indeed
a suitable option to treat patients with uncontrolled T2DM and
this independently of their baseline BMI.
Surgical Procedures
The threemajor bariatric surgical procedures, RYGB, BPD, and
SleeveGastrectomy(SG), aredescribedbelow.Themajordiffer-
ences among these three types of operations are as follows. The
stomach remnant is 30ml inRYGB, 100ml in SGand 400ml in
BPD. In theSGthere isno intestinalbypass; inRYGBthere is the
exclusion of the duodenum and the first portion of the jejunum
distal to the Treitz ligament from food transit; and in BPD, the
duodenum, the whole jejunum and the first portion of the ileum
are excluded from nutrient passage (see Fig. 1).
Roux-en-Y Gastric Bypass
This operation includes transection of the stomach with the
linear staples just below the cardia in such a way as to create
an upper pouch of about 25 ml based on the lesser curvature.
The remaining stomach is left excluded from food transit.
Next, the jejunum is divided at about 50 to 75 cm from the
Treitz ligament: the distal end is connected to the small upper
gastric pouch and the proximal end is joined to the jejunum
some 70 to 150 cm distal to the gastric anastomosis, therefore
fashioning a Roux-en-Y configuration.
Early mortality, 30 days after surgery, ranges between 0.3
and 0.5%. Excessive weight loss (EWL) is 60% at 3–5 years
and 50% at 10 years [11].
Biliopancreatic Diversion
The operation entails distal gastrectomy, leaving a gastric
pouch of about 400 ml, and closure of the duodenal stump.
The ileum is then transected at 2.5 m from the ileocecal valve,
and the distal end is brought up and anastomosed to the re-
maining stomach forming the so-called “alimentary tract”.
The proximal end of the divided ileum, which carries the bile
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and the pancreatic juice, called “biliopancreatic tract”, is con-
nected to the “alimentary tract” at 50 cm from the ileocecal
valve in an end-to-side fashion. The last 50 cm of ileum,
where food and biliopancreatic juice mix together, represents
the “common tract”.
Early mortality is around 1%. Biliopancreatic diversion has
repeatedly been shown to attain the best results in termof effec-
tiveness and durability. EWL is 75% at 3 and 10 years [12].
Sleeve Gastrectomy
Sleevegastrectomy isessentially the first stepofBPD/duodenal
switchwhere thestomach is resectedalong thegreatercurvature
and fundus, leaving a small tube of stomach in continuity with
the esophagus proximally andwith the duodenumdistally. The
gastric volume is about 100 ml [13]. Early mortality is 0.19%.
Mean EWL at 3 to 5 years is around 50% [13].
Effect of Metabolic Surgery on Glucose Disposal
and Insulin Secretion
Massive weight loss following RYGB largely ameliorates in-
su l i n s en s i t i v i t y measu r ed by the eug lycemic
hyperinsulinemic clamp (EHC) technique [14]. However,
when whole body insulin sensitivity was studied by EHC
within 1 month of RYGB, the results were controversial.
While some authors did not find any significant improvement
[14], other authors demonstrated a rapid amelioration of he-
patic insulin resistance [15].
After BPD insulin sensitivity is normalized rapidly, within
a matter of few days when the BMI is still unchanged.
Initially, the effect of BPD on glucose disposal was attributed
to the lipid malabsorption that accompanies this kind of sur-
gery [16]. However, by shifting the temporal window earlier,
just 1 and 4 weeks after BPD, when the BMI was not signif-
icantly changed, we observed that insulin sensitivity was al-
ready normalized, as shown by both the EHC and by an oral
glucose tolerance test (OGTT) [16]. This effect, might be as-
cribed to the lack of gut mucosal stimulation by nutrients after
the bypass of duodenal and jejunal tracts, which seem to se-
crete protein factors inducing insulin resistance.
Brozinick et al. [17] have reported that despite the marked
in vivo insulin resistance observed for normal-glucose tolerant
db/db mice during hyperinsulinemic clamps, their muscles
were completely insulin responsive in vitro. Therefore, they
suggested the presence of a humoral factor impairing the in-
sulin action in vivo [17].
Indeed, proteins secreted by the duodenum and jejunum
from both diabetic mice and insulin resistant humans induce
insulin resistance in both normal mice and in muscle cells by
stimulating the mTORC2 pathway [18•]. These gut condi-
tioned medium proteins induce an over-basal phosphorylation
of Akt on 473Ser, catalyzed by mTORC2, and a simultaneous
reduction of its insulin-mediated phosphorylation on 308Thr,
catalyzed by the Pyruvate Dehydrogenase Kinase 1 (PDK1),
with impairment of Akt function in myocytes in vitro [18•].
Indeed, this same picture is a characteristic of the insulin re-
sistant muscle and liver of rodents under a high fat diet [19].
Insulin secretion is increased after RYGB, but it is de-
creased after BPD as a consequence of the net improvement
in insulin sensitivity [20•].
It is interesting to note that RYGB exerts its main effect in
inducing diabetes remission through the reduction of hepatic
glucose production [15] and increased insulin secretion, while
BPD acts essentially by normalizing insulin sensitivity The
first phase insulin secretion is promptly normalized after
BPD [21••], whereas it is significantly improved, but does
not return to normality, after RYGB [22].
The very-low calorie diet (VLCD) undergone in the weeks
immediately following metabolic surgery might, indeed, con-
tribute to remove the glucotoxicity and lipotoxicty present in
diabetes. In fact, 2 weeks of VLCD alone improves the first
phase of insulin secretion [23] and hepatic insulin sensitivity
with reduction of glucose production [23]. However, we note
that a VLCD does not improve peripheral insulin resistance
[23]. These findings support the hypothesis that the reduction
of gut mucosa stimulation by nutrients, as it happens after a
VLCD, may not suppress the secretion of intestinal factor/s
SG
LAGB
RYGB
BPD
Fig. 1 Glucose and lipids activate a neuronal axis connecting the
intestine, the brain, and the liver through a nutrient sensing, probably
located in the proximal jejunum, with subsequent inhibition of the
hepatic glucose production. This nutrient sensing would be stimulated
by undigested food delivered into the jejunum after RYGB, thus
determining the reduction of the hepatic glucose production, a common
feature of this operation.When the entire jejunum is bypassed, as it occurs
after BPD, the secretion of putative insulin resistance factor/s might be
inhibited with consequent normalization of insulin sensitivity
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involved in insulin resistance, while the bypass of the duode-
num and jejunum avoiding contact of nutrients with the gut
mucosa does suppress this effect.
It iswidelyrecognizedthat theprimarydefect inT2Disinsulin
resistance [24]witha relativedeficiency in insulinsecretion.This
is the reason why some types of bariatric surgery, such as BPD,
produce T2D remission by normalizing insulin sensitivity [7].
Contrary to individuals with type 1 diabetes, those with
type 2 diabetes apparently do not show alteration in the num-
ber and dimension of pancreatic β-cells [25]. However, a
more recent autopsy study reports that, compared with lean,
non-diabetic individuals, T2D subjects have both a decrease
of the relative β-cell volume/islet and a reduction of β-cell
density [26]. Nevertheless, in spite of this reduced β-cell per-
centage in islets, the functional impairment of insulin secre-
tion was shown to be mostly reversed by reducing islet oxi-
dative stress [27]. Chronic supplementation of long-acting in-
sulin in decompensated T2D subjects increases both first and
second phase insulin secretion after an intravenous glucose
tolerance test (IVGTT) [28]. After BPD, the first phase of
insulin secretion, absent before the operation, is fully restored
[21••]. A less impressive but still significant increase is also
observed after RYGB [22], suggesting that β-cell dysfunction
can drastically improve after bariatric surgery.
Role of the Small Intestine in Glucose Homeostasis
Circulating glucose mainly derives from complex carbohy-
drates ingested with food. However, plasma glucose also orig-
inates from glycogenolysis or from gluconeogenesis from pre-
cursors such as lactate, pyruvate, amino acids, and glycerol.
Glucose concentration in the blood is regulated by a series
of mechanisms involving the small intestine, which permit the
circulating concentrations to be maintained within a narrow
range. These mechanisms include gastric emptying, glucose
absorption, and insulin secretion, all regulated by the small
intestine. Next, we will discuss the effects of bariatric surgery
on these glucose disposal steps.
Gastric Emptying
Gastric emptying, accounting for about 35% of the variance of
plasma glucose concentration at the peak after an OGTT [29],
is regulated by the opening and closure of the pylorus that
prevents the food mixed with gastric juices to enter the duo-
denum during mixing and crushing. In addition, a duodenal-
gastric feedback mechanism—including vago-vagal reflex
and hormonal signals, such as glucagon-like peptide-1
(GLP-1), peptide YY (PYY), and cholecystokinin (CCK) -
intervenes in regulating gastric emptying. Gastric emptying
influences the absorption and, thus, the circulating levels of
glucose; in turn, blood glucose levels regulate the stomach’s
emptying rate. In fact, glycaemia of 140 mg/dl or greater
slows down the gastric emptying by 20 to 30% in both dia-
betic and healthy individual [30]. Hypoglycemia, in contrast,
accelerates emptying, thus permitting more glucose absorp-
tion [31]. The accelerated transit of nutrients into the small
intestine after bariatric surgery has been regarded by some
authors as a major cause of diabetes remission, since it stim-
ulates GLP-1 and insulin secretion [32].
Subtotal gastrectomy and gastric exclusion, as after SG and
RYGB, are often accompanied by a dumping syndrome and late
hypoglycemic episodes. In the dumping syndrome, neuro-
vascular and gastrointestinal symptoms, related to the rapid gas-
tric empting and increased intestinal motility, emerge within
30 min from the meal, while late symptoms are related to hypo-
glycemia (late dumping) and appear 2 h or more after the meal.
Bender et al. [33] noted that the dumping syndrome and, in par-
ticular, hypoglycemia occur also in patientswith intact stomachs
and feeding jejunostomies, suggesting that it is driven by the
bypass of the duodenum and the first portion of the jejunum, or
by the direct delivery of nutrients into the distal jejunum.
The most accepted explanation for dumping hypoglycemia
is the excessive insulin secretion secondary to a rapid absorp-
tion of simple carbohydrates with a large early peak of blood
glucose. However, many studies demonstrated that when hy-
perglycemia was induced in subjects with partial gastrectomy
by intravenous glucose infusion in order to mimic the OGTT
curves, no reactive hypoglycemia was elicited. In fact, i.v.
infusion of glucose does not stimulate insulin secretion in
comparable amounts, nor is it followed by hypoglycemia
[34]. It is possible that oral glucose overstimulates insulin
secretion by inducing GLP-1 secretion. Indeed, the simulta-
neous infusion of glucose and GLP-1 in healthy volunteers,
mimicking the glycaemic and insulin peaks in patients with
dumping syndrome, does provoke hypoglycemia [35].
React ive hyperinsul inemic hypoglycemia with
neuroglycopenia following gastric bypass has been described
in less than 100 cases and it is related to nesidioblastosis, charac-
terized by diffuse hyperplasia and hypertrophy of pancreatic β-
cells [36]. However, what is unclear is whether congenital or
undiagnosed nesidioblastosis was already present before bariat-
ric surgery or if it developed as a consequence of theoperation. If
nesidioblastosis preceded these gastric bypass operations, it is
possible that the progressiveweight gain leading to these surger-
ies may have resulted from the life-long intake of multiple day-
time meals rich in carbohydrates prompted by patients’ need to
prevent hypoglycemic episodes.
Glucose Absorption and Nutrient Sensing
The enterocytes, representing the majority of the intestinal
epithelial cells, are highly differentiated cells with specific
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polarization. Through the apical brush-border membrane they
transport nutrients towards the baso-lateral membrane domain
and successively to the intestinal capillary system.
Enterocyte transport of glucose and galactose is per-
formed via the sodium/glucose co-transporter 1 (SGLT1).
The expression of SGLT1 increases from the duodenum
down to the ileum and it is up-regulated by the
endoluminal concentration of glucose suggesting its
function as the intestinal glucose sensor. Parker et al.
[37] have proposed that glucose uptake by SGLT1 can
stimulate the release of GLP-1 by L-cells and GIP by K-
cells given that the use of phlorizin, a competitive
blocker of sodium-glucose transporters, suppresses
incretin secretion.
Once in the enterocytes, glucose is moved to the interstitial
space by the basolateral glucose transporter (GLUT) 2, a bi-
directional transporter moving glucose outside or inside the
intestinal epithelial cells depending on the glucose gradient.
The jejunal infusion of glucose in normal rats reduces he-
patic glucose production, an effect that is reversed by
phlorizin blockade of sodium-glucose transporters located in
the mucosa of the small intestine [38]. This jejunal nutrient
sensing is also required for the rapid resolution of diabetes in
streptozotocin treated rats after duodenal-jejunal bypass [39].
During refeeding, the jejunal nutrient sensing is disrupted,
resulting in increased circulating glucose levels.
Nutrient sensing and glucose homeostasis seem to be
regulated by the ventromedial hypothalamus (VMH),
where insulin receptors are expressed [40]. VMH insulin
receptor knockdown (IRkd) mice develop hepatic insulin
resistance, glucose intolerance, increased glucagon, and
impaired insulin secretion [40]. RYGB reduces hepatic
glucose production by 58% in high fat diet rats indepen-
dently of body weight reduction, but IRkd prevents this
improvement suggesting that an increased VMH sensitiv-
ity to insulin could be mediating this effect of bariatric
surgery; however, the improvement of peripheral insulin
sensitivity was unaffected by central insulin receptor
knockdown [40]. These data were confirmed in Zucker
insulin resistant rats [41] where rapid normalization in
hepatic gluconeogenic capacity and basal hepatic glucose
production required intact vagal innervations, while this
was unnecessary for restoration of insulin sensitivity.
Interestingly, bypass of the duodenum and the proxi-
mal jejunum, as obtained by infusing simple nutrients
into the mid jejunum, is associated with a significant
improvement of whole body insulin sensitivity in both
diabetic and non-diabetic individuals [42].
Duodenal-jejunal bypass in congenitally diabetic rats
significantly improves glycemic control [43]. Avoiding
contact of nutrients with the duodenal-jejunal mucosa
and their absorption, the endoluminal sleeve also im-
proves glucose control and tolerance in humans.
Incretins
The enteroendocrine cells, although in a much lower number
than enterocytes, represent the largest endocrine organ in the
body. Until now, at least twenty different subpopulations of
enteroendocrine cells have been identified. Amongst them, K-
cell density is maximal in the duodenum, progressively de-
clining through the jejunum and ileum. The opposite is ob-
served with L cells. While K cells secrete glucose-dependent
insulinotrophic peptide (GIP), L cells produce GLP-1 and
GLP-2, although GLP-1 and GIP are co-localized in a subset
of intestinal endocrine cells in humans and pigs [44].
Nutrient-driven stimulation of GIP release in the duode-
num enhances the release of GLP-1 distally in the ileum. In
addition to GIP, many other neuropeptides and neurotransmit-
ters increase the release of GLP-1 from L cells, namely
gastrin-releasing peptide, calcitonin gene-related peptide,
and acetylcholine, the latter acting via muscarinic receptors.
Prohormone conver tase 1 produces gl icent in ,
oxyntomodulin, GLP-1, and GLP-2 from proglucagon in L
cells. GLP-1 stimulates insulin secretion, accounting for ca.
70% of the insulin secretion after oral glucose in the presence
of high levels of glucose. The hormone binds the GLP-1 re-
ceptor, which is a member of the G protein–coupled receptor
family, inducing the production of cyclic AMP. Cyclic AMP
stimulates protein kinase A (PKA), involved in the activation
of the insulin gene transcription by glucose, and activates the
guanine nucleotide exchange factor II (GEFII or Epac2) rais-
ing intracellular Ca++ concentration, fostering the release of
insulin stored vesicles. GLP-1 receptor knockout mice (GLP-
1r−/−) show glucose intolerance and reduced insulin secre-
tion after a glucose load [45].
In patients with T2D, GLP-1 improves both early and late
phases of the insulin response to glucose and suppresses glu-
cagon secretion by the pancreatic α-cells, leading to reduced
endogenous glucose production from the liver.
Similarly toGLP-1, GIP enhances intracellular cyclic AMP
generation and inhibits ATP-sensitive K+ channels, thereby
increasing intracellular Ca++ levels with consequent stimula-
tion of insulin secretion. GIP has a role in adipocyte metabo-
lism, since Gipr−/− mice show a reduction of fat depots and
are less prone to increase weight under a hypercaloric diet
[45]. In addition, GIP deficient ob/ob mice are leaner than
their wild type littermates and show an improved glucose
tolerance. The GIP antagonist Pro [3] GIP induces weight loss
in diabetic mice and improves glucose tolerance [46].
Duodenal-jejunal bypass (DJB) in congenitally diabetic
Goto-Kakizaki rats determines a significant increase in the
pancreatic islet β-cell area and a decrease of islet fibrosis
[47]. These morphologic features are associated with a func-
tional increase of insulin secretion. GLP-1 rises in the plasma
of diabetic rodents after DJB, derived from an increased pop-
ulation of cells co-expressing GIP and GLP-1 in the jejunum
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anastomosed to the stomach. Therefore, the bypass of the
duodenum and jejunum by food transit enhances the differen-
tiation of intestinal stem cells into intestinal enteroendocrine
cells producing GLP-1, with subsequently reduced β-cell
deterioration.
A large increase of incretin secretion was observed in dia-
betic, obese subjects following RYGB. Their blunted effect
was normalized just 1 month after the operation. This outcome
was not attributable to the low calorie intake following meta-
bolic surgery; in fact, incretin secretion after an OGTT was
unaffected by a low calorie diet matching the caloric intake in
RYGB patients [48].
Contrary to what happens after RYGB, BPD does not over-
stimulate incretinsecretion[22]andit ischaracterizedbyreduced
insulin secretion tomatch thenormalizationof insulin sensitivity.
In a recent study, the effect of SG was investigated in GLP-
1 receptor knockout mice, showing that the absence of GLP-1
receptor and, thus, of GLP-1 action, is not required for
obtaining the improvement of the glucose disposal, which
was similar to that observed after bariatric surgery in wild type
rodents. These data suggest that the effect of bariatric surgery
on glucose metabolism cannot be mediated by the increased
GLP-1 secretion alone.
Ghrelin
Ghrelin is a polypeptide composed of 28 amino-acid residues
principally secreted by the X/A-like cells within the gastric
oxyntic glands. Ghrelin secretion is increased in the fasting
state and suppressed by feeding, and exerts an orexigenic ac-
tion. Obese subjects show a reduction of ghrelin secretion
after meals [49]. Diet-induced weight loss is associated with
a marked increase in the circulating levels of ghrelin after the
meals, while a striking suppression of its secretion is observed
after RYGB and SG [50]. Its effect in increasing appetite is
mediated via the stimulation of NPY/agouti-related peptide
(AgRP) co-expressing neurons within the arcuate nucleus of
the hypothalamus. SG delayed T2D onset in the University of
California Davis-T2D rat, independently of body weight loss.
This effect was mediated either by decreased circulating ghrel-
in concentrations or increased circulating levels of bile acids,
adiponectin, and GLP-1 [51]. Other studies highlight the role
of decreased ghrelin secretion as a possible mechanism of
action of metabolic surgery [50].
However, vertical SG is effective in improving glucose
tolerance in both wild-type and ghrelin knockout mice when
exposed to a high-fat diet for 10 weeks before surgery [52].
This shows that, at least in rodents, ghrelin does not play a key
role in the remission of diabetes that follows bariatric surgery,
but it is rather an epiphenomenon related to the partial
gastrectomy.
Gut microbiota and glucose metabolism
The human gut microbiome is composed of more than 1012
cells per gram of feces, the majority of which are prokariotes.
Its biodiversity is enormous as it is under the control of ap-
proximately 3 million genes.
The Human Microbiome Project Consortium has studied
242healthy subjects, 129men and113women.Amonga series
ofother samples, stool specimens represented themicrobiotaof
the lower gastrointestinal tract. Themajority, 90% of themam-
malian gut microbiota, belongs to two phyla, the Bacteroidetes
and the Firmicutes. Lactobacillus andStreptococcus,which are
acid-resistant, are theonly twomicroorganisms thatcansurvive
in the stomach. The number of bacteria increases distally
throughout the small intestine so that in the ileum and, in par-
ticular, in the colon it reaches a peak.
Microbiota exert a series of actions in the intestinal medium
from bile acid metabolism to the regulation of intestinal per-
meability and the modulation of inflammation [53]. In the
large intestine, anaerobic bacteria deconjugate bile acids to
form secondary bile acids. Primary bile acids bind the nuclear
farnesoid-X receptor (FXR) while the secondary bile acids,
deoxycholic and lithocholic acids, bind the G protein-
coupled receptor (GPCR) TGR5. Interestingly, FXR impairs,
whereas TGR5 promotes, glucose homeostasis. Therefore, a
lack of transformation of primary into secondary bile acids
negatively affects glucose metabolism. In addition, the activa-
tion of TGR5 in adipose brown tissue increases energy expen-
diture and protects against diet-induced obesity [53].
The use of bile acid sequestrants in diabetic patients im-
proved glycemic control [54], possibly through the enhance-
ment of GLP-1 secretion as shown in experimental animals.
As stated above, primary bile acids bind the nuclear recep-
tor FXR that regulates the expression of genes involved in
lipid and carbohydrate metabolism and in energy expenditure.
The activation of FXR inhibits the sterol regulatory element
binding protein 1-c (SREBP1c) that mediates hepatic lipogen-
esis and activates the synthesis of apolipoprotein CII (apo
CII), resulting in the subsequent increase of triglyceride clear-
ance from the circulatory stream. In addition, FXR inhibits
hepatic apo CIII production with a consequent increase of
lipoprotein lipase activity [53]. The activation of FXR by the
synthetic agonist GW4064 or overexpression of hepatic FXR
by adenovirus-mediated gene transfer in the liver markedly
reduces blood glucose levels in both db/db and wild-type mice
[55]. FXR deficiency in genetically obese (ob/ob) mice and in
diet-induced obese mice is associated with a reduction of ad-
ipose tissue, increased insulin sensitivity and increased glu-
cose disposal [56].
The first evidence of the role played by the intestinal mi-
crobiota in energy balance was provided by Backhed et al.
[57], whose seminal paper demonstrated that germ-free ani-
mals, which were slimmer than normal littermates, became
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more obese once they received coecal bacteria of the latter
despite no change in food consumption. This effect was sec-
ondary to more efficient food energy utilization by the bacteria
that colonized the intestine of germ-free mice. An inverse
relationship of Firmicutes to Bacterioidites in lean individuals,
with increase of the former and reduction of the latter, repre-
sents a typical feature of obesity in both animals and humans.
Relatively few data are available in the literature regarding
the stool microbiota composition after bariatric surgery. Zhang
et al. [58] found a net increase of Gammaproteobacteria and a
reduction of Firmicutes in subjects who had undergone RYGB
as compared with morbidly obese ones who did not receive
the operation; however, the number of participants was very
limited at only three. As an additional limitation, these indi-
viduals were not studied preoperatively.
In Wistar rats operated with RYGB, Li et al. [59] showed a
significant increase of Proteobacteria, and in particular of
Enterobacter hormaechei, and a reduction of Firmicutes and
Bacteroidetes, in comparison to sham-operated animals. Gut
microbiota composition can determine the efficacy of energy
harvest from food. In fact, a 6-week, energy-restricted, high-
protein diet, followed by a 6-week weight-maintenance diet,
reduced adipose tissue and systemic inflammation in over-
weight or obese individuals by correcting a putative loss of
richness in low gene-count individuals [60].
Although it is possible that gut microbiota changes after
bariatric surgery play a role in the improvement of glycemic
control and amelioration of the insulin resistance status, further
research is necessary to determine the degree to which such
changes account for themetabolic benefits of bariatric surgery.
Conclusions
The small intestine exerts a primary role in glucose homeo-
stasis, as the jejunum senses the nutrients and regulates hepat-
ic glucose production and the entire small gut secretes both
GLP-1 and GIP, thereby enhancing insulin secretion. These
physiological actions are magnified by the intestinal manipu-
lations performed during bariatric surgery, with subsequent
increase of insulin sensitivity, as happens after BPD, or an
increase in insulin secretion as a consequence of incretin hy-
persecretion, as it occurs after RYGB. The possible mecha-
nism of action of bariatric surgery on diabetes is summarized
in Fig. 1. We hypothesize that bypass of the duodenum in-
creases the stimulation of a jejunal nutrient sensor that is trans-
mitted to the hypothalamus, having a negative feedback effect
to reduce liver glucose output and improve hepatic insulin
resistance. Furthermore, the exclusion of duodenum and the
entire jejunum from food transit suppresses the secretion of
intestinal hormones responsible for inducing peripheral insu-
lin resistance, with a consequent improvement of glycemic
control in T2D individuals. In addition, the changes of gut
microbiota after bariatric surgery may contribute to the ame-
lioration of hepatic insulin sensitivity.
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